Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Description

The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.

Conditions

Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.

Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Condition
Tachycardia Atrial
Intervention / Treatment

-

Contacts and Locations

Oak Lawn

Advocate Christ Medical Center Emergency Department (ACMC ED), Oak Lawn, Illinois, United States, 60453

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \> 18 years or older
  • * Able to provide informed consent
  • * Primary diagnosis AFF RVR greater than or equal to 120 bpm
  • * Diltiazem as rate control agent
  • * English speaking
  • * Hemodynamically unstable patients (SBP \<90, MAP \<65)
  • * Impaired consciousness
  • * End stage renal disease on hemodialysis or peritoneal dialysis
  • * Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
  • * Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
  • * Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
  • * Acute myocardial infarction
  • * Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
  • * Contraindications to magnesium sulfate (including myasthenia gravis)
  • * Allergy or sensitivity to any study drugs
  • * Previously enrolled in this trial during a different patient encounter
  • * Withdrew from study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Travis Hase, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

2026-12